Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171.

Cancer·2026
Same author

Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in Trials.

Journal of the American Society of Nephrology : JASN·2026
Same author

Development of a conceptual model of BKV impacts on health-related quality of life in kidney transplant recipients: a qualitative study.

Journal of patient-reported outcomes·2026
Same author

A single item for overall side effect impact: Association with clinician-reported adverse events and global health.

Clinical trials (London, England)·2026
Same author

Association Between a Co-Designed Dashboard and Use of Costly Health Services in Patients With Chronic Kidney Disease and Advanced Cancer: Propensity Score-Adjusted Difference-in-Differences Study.

Journal of medical Internet research·2025
Same author

Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.

Cancer·2025

Related Experiment Video

Updated: Jun 12, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Patient-Reported Outcomes to Inform Tolerability Characterization in Cancer Trials: A Critical Perspective on

Bill Byrom1, John Devin Peipert2,3

  • 1eCOA Science, Signant Health, Blue Bell, PA, USA.

Cancer Control : Journal of the Moffitt Cancer Center
|March 3, 2026
PubMed
Summary
This summary is machine-generated.

Patient-reported outcomes are vital in cancer drug development, but challenges remain in defining treatment tolerability. Further research is needed to improve how we interpret patient data for better clinical trial insights.

Keywords:
cancercancer treatmentpatient-reported outcomestolerabilitytoxicity

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Experiment Videos

Last Updated: Jun 12, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Health Outcomes Research

Background:

  • Patient-reported outcomes (PROs) are crucial for evaluating cancer drug toxicity and quality of life.
  • Current PRO data in early-phase trials offer insights but have limitations in determining treatment tolerability.

Purpose of the Study:

  • To examine unresolved methodological issues in using PROs for cancer drug development.
  • To highlight the need for more research rigor in assessing treatment tolerability and patient-reported outcomes.

Main Methods:

  • This commentary reviews existing challenges in PRO data interpretation.
  • It focuses on developing tolerability thresholds, direct tolerability measures, and baseline assessment strategies.

Main Results:

  • Limitations exist in inferring treatment tolerability from current PRO data.
  • Individual risk-benefit assessments vary significantly across patients, cancer types, and disease stages.

Conclusions:

  • Further research is essential to address methodological challenges in PRO assessment.
  • Improved methods will enable more robust inferences from PRO data in cancer clinical trials.